Tumor-derived Evs enhance cancer metastasis and drug resistance partially due to PD-L1 delivered from tumor-derived Evs, which acts as a novel RNA binding protein to increase drug resistance in cancer cells by affecting mRNA stability of various mRNAs involved in cellular response to DNA damage. The gene discussed is CD274; the disease is neoplasm.